Hepatology

HBV education led by healthcare providers, decentralized testing, and strategies with more framework-driven mechanisms had the greatest impact on testing uptake.

Physicians who received pharmaceutical industry payments related to 4 different direct-acting antivirals were more likely to prescribe these medications.

Findings from the prospective cohort study suggest the value of serum Z polymer levels as a non-invasive disease-specific biomarker in patients with homozygous ZZ AATD liver disease.

Magnetic resonance elastography and transient elastography did not accurately predict high-grade fibrosis on liver biopsy in children with MASLD.

Heplisav-B provided a greater vaccine completion rate and higher HBV seroprotection than the conventional 3-dose Recombivax HB in thoracic organ transplant candidates.

Meta-analysis findings suggest a significant association between MASLD and serious bacterial infection risk.

Obesity and advanced fibrosis were independent predictors of impaired health-related quality of life in people with T2D.

Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.

With HepQuant DuO and SHUNT tests, investigators could categorize patients with sclerosing cholangitis into low, moderate, and high disease severity subgroups.

Reau explains the importance of second- and third-line treatment in PBC and the potential implications of no longer having OCA after a negative FDA advisory committee meeting.

Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.

Moser reviews ongoing unmet needs in PBC and how the addition of 2 new second-line treatment options has changed the treatment landscape.

Mathew emphasizes the importance of routine liver cancer screening in patients with advanced liver disease and the need to overcome insurance barriers for HCC panel testing.

Iordache emphasizes the importance of a multidisciplinary approach to liver disease care in pregnant patients and the need for patient education.

Legaspi reviews different treatment options for managing ascites, ranging from limiting dietary sodium intake to diuretic use and therapeutic paracentesis.

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.

Low birth weight and being small for gestational age were linked to a greater risk of developing pediatric-onset MASLD and progressive liver disease.

Findings underscore the importance of alcohol cessation in patients with steatotic liver disease, suggesting a synergistic effect between steatosis and alcohol on disease progression.

There was no difference in the incidence of BKPyV, CMV, or EBV in patients who received HCV NAT-positive donor kidneys versus those who received HCV NAT-negative donor kidneys.

People with chronic liver disease were more likely to experience healthcare barriers and require recurrent acute care compared to those with COPD and/or CVD.

Findings support the use of FIB-4’s low cut-off for ruling out severe fibrosis and cirrhosis as well as the use of Forns index’s high cut-off for significant fibrosis in chronic HCV.

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.